Lucira Health
Next generation infectious disease test kits
- Status
- Public
- Stage
- Growth
- Team size
- 43
- Location
- Emeryville, CA, USA
- Category
- Medical Devices & Diagnostics
- Sector
- Diagnostics
About Lucira Health
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.
Clinical trials
3 registered trials with this company as lead sponsor, 2020 to 2022.
- Status
- Completed (3)
- Conditions
- Covid19, Corona Virus Infection, COVID-19, Influenza, SARS (Severe Acute Respiratory Syndrome)
NCT06141824, NCT04720235, NCT04720794
Source: ClinicalTrials.gov.
Federal research funding
10 NIH awards totalling $6,619,659, FY2012 to FY2022.
- Low-Cost Instrument-free Point-of-Care Test for Chlamydia and Gonorrhea
- Low-Cost Instrument-free Point-of-Care Diagnostic for Neisseria gonorrhoeae
Source: NIH RePORTER.
Securities filings
2 Form D filings on record, 2019 to 2020.
Filed as Lucira Health, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
